CPIX - カンバ―ランド・ファ―マシュ―ティカルズ (Cumberland Pharmaceuticals Inc.) カンバ―ランド・ファ―マシュ―ティカルズ

 CPIXのチャート


 CPIXの企業情報

symbol CPIx
会社名 Cumberland Pharmaceuticals Inc (カンバ―ランド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 カンバーランド・ファーマシューティカルズ(Cumberland Pharmaceuticals Inc.)はブランド付き処方薬製品の取得、開発及び商品化に従事する医薬品専門会社である。同社は病院ケアと消化器市場向けの処方薬製品を開発・商業化する権利の取得を中心を行う。同社の製品ポートフォリオには、アセトアミノフェン中毒向けの治療薬「Acetadote」(アセチルシステイン)注射剤、疼痛・発熱向けの注射治療薬「Caldolor」(イブプロフェン)注射剤、下剤の処方薬の1種である経口液剤「Kristalose」(ラクツロース)、並びに肝腎症候群(HRS)を患っている患者の治療のための注射剤「Hepatoren」(イフェトロバン)が含まれる。平成23年12月31日現在、「Hepatoren」は第II相臨床開発段階における。平成23年11月、同社は「Kristalose」ブランドと関連する残る権利を取得した。平成23年12月期決算期において、同社は「Hepatoren」ブランド名で開発する後期段階の製品候補の権利を取得した。   カンバ―ランド・ファ―マシュ―ティカルズは米国の医薬品会社。処方箋薬の買収、開発、商業化を行う。主に救急薬と胃腸薬に重点を置く。主な製品はアセトアミノフェン中毒治療用注射剤「アセタド―テ」、急性疼痛・発熱治療用静脈内投与イブプロフェン「カルドロ―ル」など。   Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.
本社所在地 2525 West End Avenue Suite 950 Nashville TN 37203 USA
代表者氏名 A. J. Kazimi A.J.カジミ
代表者役職名 Chairman of the Board Principal Executive Officer
電話番号 +1 615-255-0068
設立年月日 36161
市場名 NASDAQ National Market System
ipoyear 2009年
従業員数 84人
url www.cumberlandpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cpix
adr_tso
EBITDA EBITDA(百万ドル) -2.33567
終値(lastsale) 5.8
時価総額(marketcap) 90295090.2
時価総額 時価総額(百万ドル) 89.20532
売上高 売上高(百万ドル) 41.59758
企業価値(EV) 企業価値(EV)(百万ドル) 50.49531
当期純利益 当期純利益(百万ドル) -4.84351
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cumberland Pharmaceuticals Inc. revenues increased 2% to $18.8M. Net loss before extraordinary items decreased 50% to $3.2M. Revenues reflect Caldolor increase of 22% to $6.5M Vaprisol increase of 85% to $1.8M Kristalose increase of 15% to $2.1M. Lower net loss reflects Selling and Marketing decrease of 2% to $9.7M (expense) Interest Income increase of 90% to $232K (income).

 CPIXのテクニカル分析


 CPIXのニュース

   Cumberland Pharmaceuticals (CPIX) Q1 Earnings and Revenues Miss Estimates  2020/05/20 22:15:03 Zacks Investment Research
Cumberland (CPIX) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Cumberland Pharmaceuticals Reports First Quarter 2020 Financial Results & Company Update  2020/05/20 20:05:00 PR Newswire
NASHVILLE, Tenn., May 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today provided a company update and announced first quarter 2020 financial results. Net revenues from…
   Zacks.com featured highlights include: MagnaChip Semiconductor, PJT Partners, eXp World and Cumberland Pharmaceuticals  2020/05/01 11:04:00 Zacks Investment Research
Zacks.com featured highlights include: MagnaChip Semiconductor, PJT Partners, eXp World and Cumberland Pharmaceuticals
   Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor® to Help Treat High Fevers Associated With Coronavirus Infections  2020/03/31 21:00:00 Benzinga Feeds
NASHVILLE, Tenn. , March 31, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) a specialty pharmaceutical company, today announced a national initiative to support hospitals and clinics that use Caldolor ® ( ibuprofen ) injection for the treatment of patients with fever, severe hyperthermia and other symptoms associated with COVID-19 infections. Cumberland's initiative includes the availability of special supply and financial arrangements, including favorable pricing and payment terms for hospitals and clinics to help ensure timely access to Caldolor during this healthcare crisis. For more information regarding this special access, contact Jim Herman , Cumberland's Senior Vice President National Accounts at jherman@cumberlandpharma.com . "Reducing a very high fever can be particularly important in certain patients infected by COVID-19 and we are removing logistical and financial obstacles that might stand in the way of quickly getting health care providers a very effective, fast-acting and safe fever-reducing drug.
   Cumberland Pharmaceuticals : Investor Presentation - Q4 2019 | MarketScreener  2020/03/18 21:28:21 MarketScreener
Corporate Presentation Nasdaq CPIX Safe Harbor Statement … | March 18, 2020
   Cumberland Pharmaceuticals (CPIX) Q1 Earnings and Revenues Miss Estimates  2020/05/20 22:15:03 Zacks Investment Research
Cumberland (CPIX) delivered earnings and revenue surprises of -50.00% and -11.93%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Cumberland Pharmaceuticals Reports First Quarter 2020 Financial Results & Company Update  2020/05/20 20:05:00 PR Newswire
NASHVILLE, Tenn., May 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today provided a company update and announced first quarter 2020 financial results. Net revenues from…
   Zacks.com featured highlights include: MagnaChip Semiconductor, PJT Partners, eXp World and Cumberland Pharmaceuticals  2020/05/01 11:04:00 Zacks Investment Research
Zacks.com featured highlights include: MagnaChip Semiconductor, PJT Partners, eXp World and Cumberland Pharmaceuticals
   Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor® to Help Treat High Fevers Associated With Coronavirus Infections  2020/03/31 21:00:00 Benzinga Feeds
NASHVILLE, Tenn. , March 31, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) a specialty pharmaceutical company, today announced a national initiative to support hospitals and clinics that use Caldolor ® ( ibuprofen ) injection for the treatment of patients with fever, severe hyperthermia and other symptoms associated with COVID-19 infections. Cumberland's initiative includes the availability of special supply and financial arrangements, including favorable pricing and payment terms for hospitals and clinics to help ensure timely access to Caldolor during this healthcare crisis. For more information regarding this special access, contact Jim Herman , Cumberland's Senior Vice President National Accounts at jherman@cumberlandpharma.com . "Reducing a very high fever can be particularly important in certain patients infected by COVID-19 and we are removing logistical and financial obstacles that might stand in the way of quickly getting health care providers a very effective, fast-acting and safe fever-reducing drug.
   Cumberland Pharmaceuticals : Investor Presentation - Q4 2019 | MarketScreener  2020/03/18 21:28:21 MarketScreener
Corporate Presentation Nasdaq CPIX Safe Harbor Statement … | March 18, 2020
   Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor® to Help Treat High Fevers Associated With Coronavirus Infections  2020/03/31 21:00:00 Benzinga Feeds
NASHVILLE, Tenn. , March 31, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) a specialty pharmaceutical company, today announced a national initiative to support hospitals and clinics that use Caldolor ® ( ibuprofen ) injection for the treatment of patients with fever, severe hyperthermia and other symptoms associated with COVID-19 infections. Cumberland's initiative includes the availability of special supply and financial arrangements, including favorable pricing and payment terms for hospitals and clinics to help ensure timely access to Caldolor during this healthcare crisis. For more information regarding this special access, contact Jim Herman , Cumberland's Senior Vice President National Accounts at jherman@cumberlandpharma.com . "Reducing a very high fever can be particularly important in certain patients infected by COVID-19 and we are removing logistical and financial obstacles that might stand in the way of quickly getting health care providers a very effective, fast-acting and safe fever-reducing drug.
   Cumberland Pharmaceuticals : Investor Presentation - Q4 2019 | MarketScreener  2020/03/18 21:28:21 MarketScreener
Corporate Presentation Nasdaq CPIX Safe Harbor Statement … | March 18, 2020
   The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy  2020/02/27 12:35:07 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.
   Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product  2020/01/07 21:05:00 PR Newswire
NASHVILLE, Tenn., Jan. 7, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with a focus on hospital acute care, today announced the launch of Caldolor® (ibuprofen) Injection in a ready-to-use bag that may be administered without…
   Cumberland Pharmaceuticals To Hold Update Call To Discuss Recent Major Developments  2020/01/02 14:35:00 PR Newswire
NASHVILLE, Tenn., Jan. 2, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will hold an update call to discuss recent developments and plans for the Company's Caldolor® and RediTrexTM brands after the market closes on Tuesday, January 7, 2020….

 関連キーワード  (医薬品 米国株 カンバ―ランド・ファ―マシュ―ティカルズ CPIX Cumberland Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)